An independent two-stage DCF analysis by a frontier AI model.
DaVita is the quintessential defensive, wide-moat business. Alongside Fresenius, it operates a functional duopoly in the US outpatient dialysis market. Because end-stage renal disease requires treatment three times a week for survival, DaVita's revenue is highly insulated from economic recessions. This predictability allows the company to generate massive, reliable free cash flow—consistently exceeding $1.3B annually—which management aggressively uses to repurchase shares, driving tremendous value for remaining shareholders (like Berkshire Hathaway).
The market frequently discounts DaVita due to its heavy reliance on government reimbursement rates and headline risks surrounding legislation. However, this pessimism is fully priced in at current levels near $150. Even with highly conservative growth assumptions (3% FCF growth) and acknowledging the risk of a shifting commercial payer mix, the DCF model indicates the stock is undervalued, offering a nearly 20% margin of safety for value-conscious investors seeking a defensive anchor.
A highly conservative 3% FCF growth rate is modeled, reflecting the sluggish volume growth of the core US dialysis market and the ongoing pressures of clinical labor inflation balanced against modest reimbursement rate increases.
A 7% discount rate reflects the exceptionally defensive, non-cyclical nature of DaVita's revenue. Dialysis is a life-sustaining treatment, ensuring highly predictable and stable cash flows regardless of macroeconomic conditions.
A 1.5% terminal growth rate assumes the company will essentially grow in line with the incident rate of ESRD in the aging US population, acting as a perpetuity cash cow.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 0.5% | 1.0% | 1.5% | 2.0% | 2.5% |
|---|---|---|---|---|---|
| 0.5% | $218.17 | $178.50 | $151.04 | $130.90 | $115.50 |
| 1.0% | $245.44 | $196.35 | $163.63 | $140.25 | $122.72 |
| 1.5% | $280.50 | $218.17 | $178.50 | $151.04 | $130.90 |
| 2.0% | $327.25 | $245.44 | $196.35 | $163.63 | $140.25 |
| 2.5% | $392.70 | $280.50 | $218.17 | $178.50 | $151.04 |
■ Undervalued vs current price ■ Overvalued vs current price
DaVita and Fresenius Medical Care collectively control an estimated 70-80% of the outpatient dialysis market in the United States. High regulatory barriers to entry (Certificate of Need laws) make it nearly impossible for new entrants to reach scale.
Payer mix. While government programs (Medicare) cover almost 90% of its patients, they reimburse at or near cost. DaVita relies almost entirely on the remaining 10% of patients covered by commercial insurance (who pay significantly higher rates) to generate its profit.
Yes. At current prices, the intrinsic value calculation suggests a ~19% margin of safety. It is a highly defensive, cash-generating business backed by a massive share repurchase program.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.